相似文献
1
COX-2 inhibitors in NSCLC: never-ending story or misplaced?
Transl Lung Cancer Res. 2018 Sep;7(Suppl 3):S191-S194. doi: 10.21037/tlcr.2018.04.17.
2
VEGF inhibitors in -mutated lung cancer: a never-ending story?
Ann Transl Med. 2018 Dec;6(23):446. doi: 10.21037/atm.2018.11.20.
3
[Cyclooxygenase inhibitors: a never ending story?].
G Ital Cardiol (Rome). 2006 Jul;7(7):505-7.
4
The never-ending story on coronary calcium: is it predictive, punitive, or protective?
J Am Coll Cardiol. 2015 Apr 7;65(13):1283-1285. doi: 10.1016/j.jacc.2015.02.024.
5
Structures and energetics of the tert-butyl cation: the final answer or a never-ending story?
Chemistry. 2011 Sep 12;17(38):10552-5. doi: 10.1002/chem.201100797.
6
Response letter: treatment of patent ductus arteriosus when pharmacologic or conservative approaches fail-a never-ending story.
J Thorac Dis. 2020 Jun;12(6):3445-3447. doi: 10.21037/jtd-20-1802.
7
Pain and sedation during colonoscopy - a never ending story.
Endosc Int Open. 2016 May;4(5):E538-9. doi: 10.1055/s-0042-106085.
8
Colorectal Liver Metastases: A Never Ending Story.
Ann Coloproctol. 2016 Jun;32(3):87. doi: 10.3393/ac.2016.32.3.87. Epub 2016 Jun 30.
9
Luminescence: The Never-Ending Story.
Top Curr Chem (Cham). 2016 Aug;374(4):44. doi: 10.1007/s41061-016-0044-0.
10
Inactive Carriers of Hepatitis B Virus: A Never Ending Story.
GE Port J Gastroenterol. 2015 Apr 18;22(2):43-44. doi: 10.1016/j.jpge.2015.03.006. eCollection 2015 Mar-Apr.
引用本文的文献
1
Insights into the Mechanisms of Action of Proanthocyanidins and Anthocyanins in the Treatment of Nicotine-Induced Non-Small Cell Lung Cancer.
Int J Mol Sci. 2022 Jul 18;23(14):7905. doi: 10.3390/ijms23147905.
2
Therapeutic Implications of Tumor Microenvironment in Lung Cancer: Focus on Immune Checkpoint Blockade.
Front Immunol. 2022 Jan 7;12:799455. doi: 10.3389/fimmu.2021.799455. eCollection 2021.
本文引用的文献
1
Phase III Randomized, Placebo-Controlled, Double-Blind Trial of Celecoxib in Addition to Standard Chemotherapy for Advanced Non-Small-Cell Lung Cancer With Cyclooxygenase-2 Overexpression: CALGB 30801 (Alliance).
J Clin Oncol. 2017 Jul 1;35(19):2184-2192. doi: 10.1200/JCO.2016.71.3743. Epub 2017 May 10.
2
Clinical Profile of Cyclooxygenase-2 Inhibitors in Treating Non-Small Cell Lung Cancer: A Meta-Analysis of Nine Randomized Clinical Trials.
PLoS One. 2016 Mar 23;11(3):e0151939. doi: 10.1371/journal.pone.0151939. eCollection 2016.
3
Cox-2 in non-small cell lung cancer: a meta-analysis.
Clin Chim Acta. 2013 Apr 18;419:26-32. doi: 10.1016/j.cca.2013.01.012. Epub 2013 Feb 4.
4
Randomized, placebo-controlled phase III study of docetaxel plus carboplatin with celecoxib and cyclooxygenase-2 expression as a biomarker for patients with advanced non-small-cell lung cancer: the NVALT-4 study.
J Clin Oncol. 2011 Nov 10;29(32):4320-6. doi: 10.1200/JCO.2011.35.5214. Epub 2011 Oct 11.
5
Effect of celecoxib on survival in patients with advanced non-small cell lung cancer: a double blind randomised clinical phase III trial (CYCLUS study) by the Swedish Lung Cancer Study Group.
Eur J Cancer. 2011 Jul;47(10):1546-55. doi: 10.1016/j.ejca.2011.03.035. Epub 2011 May 10.
6
Hallmarks of cancer: the next generation.
Cell. 2011 Mar 4;144(5):646-74. doi: 10.1016/j.cell.2011.02.013.
7
Cigarette smoking, cyclooxygenase-2 pathway and cancer.
Biochim Biophys Acta. 2011 Apr;1815(2):158-69. doi: 10.1016/j.bbcan.2010.11.005. Epub 2010 Dec 13.
8
The role of cyclooxygenase-2 in cell proliferation and cell death in human malignancies.
Int J Cell Biol. 2010;2010:215158. doi: 10.1155/2010/215158. Epub 2010 Mar 17.
9
Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability.
Carcinogenesis. 2009 Jul;30(7):1073-81. doi: 10.1093/carcin/bgp127. Epub 2009 May 25.
10
Cancer-related inflammation.
Nature. 2008 Jul 24;454(7203):436-44. doi: 10.1038/nature07205.
Zotero 插件